The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price ...
Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...
Zacks Investment Research on MSN
Ocugen stock surges 75% year to date: What's in store for 2026?
Ocugen OCGN is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms ...
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago. These figures are ...
Shares of Ocugen Inc. OCGN advanced 5.71% to $1.48 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.64% to 6,878.49 and the ...
In the fourth quarter of 2025, Ocugen ’s Board, following a review by its Compensation Committee and external consultant, approved an additional grant of 9,369,604 performance restricted stock units ...
Good morning, and welcome to Ocugen's Third Quarter 2025 Financial Results and Business Update. Please note that this call is being recorded at this time. [Operator Instructions] I will now turn the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback